Have you struggled with failed implantation or been told you have a thin endometrium? If you’ve been diagnosed with Asherman syndrome, you’re not alone—and now, thanks to regenerative medicine, there’s new hope. This article explores a revolutionary stem cell therapy that’s transforming the landscape of reproductive health.
What Is Asherman Syndrome and Why Does It Matter?
Asherman syndrome is a condition where scar tissue (adhesions) forms inside the uterus, often after uterine surgery like a D&C or following infections. This scar tissue disrupts the normal function of the endometrium—the uterine lining crucial for implantation and pregnancy. Women with this condition frequently experience:
- Irregular or absent periods
- Recurrent pregnancy loss
- Failed embryo implantation
- Infertility, even with IVF
In many cases, a thin endometrium accompanies Asherman syndrome, making it even harder for embryos to implant and thrive.
Why Conventional Treatments Often Fall Short
Traditional treatments like hysteroscopic surgery and hormone therapy aim to remove adhesions and stimulate endometrial growth. However, they come with significant limitations:
- High recurrence of scar tissue
- Inadequate restoration of endometrial function
- No effective solutions for persistent thin endometrium
- Limited improvement in fertility outcomes
These setbacks often leave women emotionally and physically drained, searching for a more definitive and lasting solution.
Stem Cell Therapy for Asherman Syndrome
Innovative science is now offering what many thought was impossible: the regeneration of the endometrium through autologous CD133+ stem cells. This advanced therapy is not experimental—it has been clinically tested, with promising results in Phase I/II trials.
What Makes Stem Cell Therapy Different?
Unlike conventional approaches, stem cell therapy targets the root cause: damage and degeneration of the endometrial lining. By using the patient’s own stem cells, this therapy stimulates:
- Angiogenesis (formation of new blood vessels)
- Endometrial repair and thickening
- Restoration of normal menstrual cycles
- Improved implantation rates and pregnancy success
Introducing PAULA: Personalized Cell Therapy for Endometrial Regeneration
At the forefront of this revolution is PAULA cell therapy, —an advanced therapy developed by leading experts in reproductive medicine. PAULA stands for Patient-specific Autologous endometriaL Advanced therapy and uses CD133+ stem cells harvested from the patient’s bone marrow.
How PAULA Works
- Mobilization of stem cells from the bone marrow using G-CSF
- Leukapheresis to collect blood and isolate CD133+ cells
- Processing in GMP-certified labs
- Intra-arterial infusion of the cells into the uterine arteries
- Endometrial regeneration, promoting a thick, receptive lining
This therapy is minimally invasive and performed on an outpatient basis over six carefully supervised visits.
Clinical Evidence and Results
PAULA has demonstrated:
- Significant increase in endometrial thickness
- Reduced miscarriage rates
- Improved chances of natural or assisted conception
Its safety and efficacy have earned it Orphan Drug Designation by both the FDA and EMA, highlighting its potential to fill a critical gap in women’s reproductive healthcare.
Is PAULA Right for You?
You may be a candidate if you:
- Have been diagnosed with moderate to severe Asherman syndrome
- Suffer from a persistently thin endometrium
- Have experienced repeated IVF failures
- Seek a non-invasive, regenerative approach backed by science
What Sets This Treatment Apart
- ✅ Personalized: uses your own cells
- ✅ Scientifically validated: backed by peer-reviewed studies
- ✅ Minimal risk of rejection or side effects
- ✅ Designed for women who haven’t responded to other treatments
This therapy offers something truly different: not another trial-and-error treatment, but a path toward true healing and renewed fertility.
Your Journey Toward Healing Starts Here
If you’re ready to explore a scientifically grounded and compassionate approach to Asherman syndrome, PAULA may be the solution. Many women have already begun their path to motherhood through this groundbreaking therapy.
We are looking for patients with this condition for the phase III clinical trial that will start at the end of this year.
Learn more or inquire about eligibility at endorenew.com or send us an email at inquiries@endorenew.com .